Hepatitis C Virus is an important cause of preventable morbidity and mortality among Injecting Drug Users worldwide.
Introduction
There has been an exponential increase of Hepatitis C Virus (HCV) infection among Injecting Drug Users (IDUs) globally in the past one decade even when there are evidence of decline of HIV prevalence among the IDUs, HCV remains alarmingly high despite all efforts. 1, 2 Couple with high economic burden of treating HCV as well as care for the rehabilitation of IDUs, interests among researchers has remain high towards understanding the matrix of HCV among IDUs among others. 3 The high morbidity and mortality due to HCV among IDUs could easily be preventable. The World Health Organization (WHO) has still reported inadequacy of understanding of treatment, care and prevention of HCV infection among IDUs.
HCV is easily transmissible by sharing of non-sterile syringe among IDUs, who already have documented high population prevalence of 43-67% among life-time users. The infection has been at an epidemic proportion since the 1960s until 1990s thus preceding and exceeding the epidemics of Human Immune deficiency Virus (HIV) globally. In the United States, The City of New York alone, 90% of IDUs had HCV infection in the 1990s. 4 The global prevalence of HCV has recently been estimated at 1.7% or 115 million cases which yet exceed the global burden of HIV/AIDS. 5 There are few studies targeting IDUs in the Middle East in the recent past. 6 However no previous study has assessed HCV among IDUs in the Kingdom of Saudi Arabia (KSA) and the prevalence of IDUs among people aged 15-64 years in KSA has also not been well established. 7 This has constituted a huge gap in the harm reduction programs for IDUs in KSA. A combined regional estimate of 5-60% HCV prevalence among IDUs has been reported from a review of published studies in the Middle East. 8 Since significant HCV prevalence reduction has been reported among IDUs subjected to intervention programs like needle and syringe exchange program (SEP) and medication assisted treatment (MAT). 4 This study aims at determining the prevalence of HCV infection among IDUs population in KSA and to identify significant correlates associated with HCV infection among IDUs population in KSA.
Materials and Methods
We conducted a point cross sectional survey between May 2012 through Nov 2012 among IDUs accessing care at AlAmal Hospital Jeddah in the KSA. The AlAmal Hospital Jeddah is a referral center for treatment of drug addiction in KSA. Participants who were either on follow up, accessing care on first presentation or referred from another center, were recruited during contacts in the specialist's clinic. IDUs who were eligible for the survey were defined as any person aged between 18 to 49 years who has injected drugs recreationally at least once in the past 12 months. To produce a national-level estimate of HCV prevalence among IDUs, a sample size was calculated, with an assumed HCV prevalence of 5%, a design effect of 1.5-2.0 and a set precision level of 0.05, a total sample to be achieved was 300. No incentive was given for participation and subjects who declined informed consent were assured of continuous care in the center irrespective of their decision not to participate. After obtaining consent, data were collected using interviewer administered study tool by Doctors and Nurses who were trained to administer the tool. A brief rejecter questionnaire was developed for any IDU who declined participation to allow for an estimation of the attrition rate.
Data were collected on socio-demographic characteristics, drug use, and high risk sexual behavior in the past 6 months. Drug use-related questions included the age at which the patient started use and the route of drug administration. Injection drug use was defined as any injection of drugs during the patient's lifetime (Have you ever used drugs by injection?).
A pretest counseling session conducted by certified HCV counselors at the time of phlebotomy were performed for every participant after questionnaire administration. Blood samples were then collected for HCV antibodies detection using ELISA and a confirmatory test. Participants were asked to return two weeks after the baseline visit, for their HCV antibody test results and posttest counseling.
All participants were given information on HCV infection, including details on the natural history of HCV infection and the high infectivity rate of HCV, participants were counseled to avoid sharing needles, syringes, and other injection equipment to reduce the risk of HCV transmission and were counseled to use needle exchange programs. However, participants found to be positive for HCV antibody were referred to a counselor with expertise in HCV infection for more elaborate discussion on how to lessen the risk of progression to liver disease including the need to cease or reduce alcohol ingestion. Safe injection practices were encouraged and the HCV-positive participants were referred to see a hepatologist physician for treatment.
Data was analyzed using Statistical Package for the Social Sciences (SPSS). First uni-variate and then cross tabulation was used to explain possible relationship between the variables. To determine the significance of association we applied chisquare test for categorical variables. The significance level (P-value) was set as <0.05 at 95% CI.
Results
A total of 300 male IDUs consented and participated in the survey among which majority were single 170 (56.7%). Of the single participants, 78 (45.9%) were HCV positive. However, most of the participants were employed 178 (59.3%) although there was higher prevalence of HCV with positive results among 54 (44.3%) of the 122 (40.7%) unemployed IDUs. Most of the participants were educated to the level of secondary school only 133 (44.3%), however those having only the primary school level of education have higher prevalence of HCV with prevalence of 38(57.6%). IDUs who initiated injection at age greater than 15 years were more among the surveyed participants, 266 (88.7%) and also had higher prevalence of HCV infection 126 (47.4%) compared with those who initiate injection below the age of 15 years (Table 1) . About 49 (16.3%) of the respondents has legal problems as at time of the participation in this survey. 26 (%) have history of family abuse. And 66 (22.0%) of the IDUs uses alcohol at least once in a day. Overall prevalence of HCV antibody among IDUs surveyed was 42.7%.
HCV antibody status was tested against clinical status of respondents using chisquare test of association. Highly significant association was found between HCV antibodies status with clinical statuses of drug abuses and drug dependence. Also on test of association with specific drugs, opioids, cannabis, cocaine, amphetamines and alcohol. There was no significant association between clinical status of drug induced sleep disorder, drug induced sexual disorder, delusion, drug induced psychosis and HCV antibodies status.
Discussion
This study attempted to provide scientific evidence of burden of HCV among increasing population of IDUs in KSA and to also determine association between HCV and clinical status of participants ( Table 2 ). The study shows relatively lower prevalence of HCV among IDUs in KSA (42.7%) as compared with the global prevalence rates of 55-95% as reported elsewhere in the literature. 9 Yet, this study shows KSA has higher prevalence of HCV among IDUs compared with other middle east countries such as Iran with 34% HCV prevalence among IDUs, 6 and even among some North American countries such as Brazil. 10 Participants with low level primary education, history of family abuse, and unemployed have higher prevalence of HCV antibodies. Only male were enrolled in this study as there were no female IDUs appearing in the study center throughout the study duration. Previous studies have though documented gender variations in HCV among IDUs. 11, 12 Analysis of baseline characteristics in Table 2 above shows HCV prevalence is considerably high across all characteristics. Whereas most previous studies 14 The treatment for HCV is usually very expensive, complicated, and may not always be successful. Currently, the best treatment available consists of pegylated interferon alpha plus ribavarin, which produces a sustained virologic response in 30 to 80% of treated patients. Response rates vary depending on the HCV genotype of the patient, with lower response rates of 30 to 40% seen in patients infected with genotype 1. 15 Treatment with pegylated alpha 2a interferon cost $270 US per week and needs to be taken weekly for six months to one year. In Saudi Arabia, this cost of treatment will ranges from 1000-1200 SAR per week, with 44% of the studied IDUs as unemployed, cost of care can be a significant factor in driving the infected IDUs to chronic disease state.
Article
In an attempt to reduce the burden of damages from illegal injection practices, public health strategies aimed at harm reductions among IDUs have been used in many countries with varying degrees of outcomes. In Saudi Arabia to the best of our knowledge there are no instituted government funded harm reduction projects targeting IDUs population.
The harm reduction programs, treatment centers and substituted prescription have been used to reduce both the health and social problems associated with injection drug practices
Conclusions
Our study shows the prevalence of HCV among IDUs in Saudi Arabia is relatively high as in most other parts of the world. IDUs in Saudi Arabia are mostly unemployed with low level of education with associated clinical sequela. Urgent public health strategies are needed to provide harm reduction measures among IDUs in Saudi Arabia.
